Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is unchanged from the same period last year. The company reported quarterly sales of $109.976 million which beat the analyst consensus estimate of $101.050 million by 8.83 percent. This is a 2.17 percent increase over sales of $107.642 million the same period last year.
Organogenesis Hldgs Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $109.976M Beat $101.050M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.